MedPath

Geron Stock Rallies More Than 60% in a Year: Here's Why

Geron Corporation's stock surged over 60% in the past year, driven by the FDA approval and successful commercial launch of Rytelo for treating myelodysplastic syndromes, alongside strong financial backing and promising clinical trial results.

For Geron Corporation (GERN), 2024 marked a pivotal year with the FDA approval and subsequent commercial launch of Rytelo (imetelstat) in June, targeting low- to intermediate-1 risk myelodysplastic syndromes (MDS) accompanied by transfusion-dependent anemia. This milestone contributed to a 61.1% surge in Geron's shares over the past year, contrasting sharply with a 15.6% decline in the industry.
Rytelo's approval not only marked Geron's first FDA-approved product but also demonstrated strong demand trends, with sales reaching $28.2 million in its first full quarter post-launch, surpassing the company's expectations. The drug addresses a high unmet need in lower-risk MDS, and Geron anticipates sustained demand and momentum for Rytelo.
In December, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending Rytelo's approval in the EU, with a decision expected in the first half of 2025. Additionally, Geron is exploring Rytelo's potential in the phase III IMpactMF study for relapsed/refractory myelofibrosis (MF), with early findings suggesting the drug's tolerability in combination with ruxolitinib for MF treatment.
Financially, Geron bolstered its position through a $375 million funding initiative, including a synthetic royalty agreement with Royalty Pharma and a senior secured term loan from Pharmakon Advisors. This financial strategy supports Rytelo's commercial launch in the U.S. and potential EU market entry, alongside ongoing MF studies.
Moreover, Geron's financial outlook has improved, with 2024 loss estimates narrowing from 26 cents to 25 cents per share and 2025 estimates improving from 10 cents to 6 cents per share over the past 60 days. Geron currently holds a Zacks Rank #3 (Hold), indicating a neutral stance in the investment community.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Geron Corporation Advances in Myeloid Hematologic Malignancies Treatment

Geron Corporation, a biopharmaceutical company, is making strides in the treatment of myeloid hematologic malignancies with its drug imetelstat, currently in Phase 3 clinical trials.

FDA Approves Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-versus-Host Disease

The FDA has approved Ryoncil (remestemcel-L-rknd) as the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients.
Ryoncil's approval was based on a Phase III trial demonstrating a 70% overall response rate in children with SR-aGVHD after 28 days of treatment.

CHMP Recommends Approval of Geron's Rytelo for Lower-Risk Myelodysplastic Syndromes

The Committee for Medicinal Products for Human Use (CHMP) has recommended Rytelo (imetelstat) for approval in the EU for transfusion-dependent anemia due to lower-risk myelodysplastic syndromes.
Rytelo targets patients who have had an unsatisfactory response to or are ineligible for erythropoietin-based therapies, offering a new treatment option.

Orthocell's Remplir Shows Positive Results in Nerve Repair Study, Eyes FDA Clearance

Orthocell's Remplir nerve repair study met all required endpoints, demonstrating safety and effectiveness in repairing peripheral nerves.
The study showed return of motor and sensory function with no adverse tissue reactions, supporting Remplir's biocompatibility.

Soleno Therapeutics Faces Losses Despite DCCR Progress for Prader-Willi Syndrome

Soleno Therapeutics reported a net loss of $76.6 million for the period ending September 30, 2024, a 605% increase compared to the same period in 2023.
The company's New Drug Application (NDA) for DCCR (Diazoxide Choline) Extended-Release tablets, a treatment for Prader-Willi syndrome, is under Priority Review by the FDA.

Geron's Rytelo Sees Strong Launch, H.C. Wainwright Assigns 'Buy' Rating

Geron's Rytelo (imetelstat) received FDA approval on June 6, 2024, for transfusion-dependent anemia in certain myelodysplastic syndromes.
Early performance shows promise, with 160 patients starting treatment within the first month, and positive feedback from physicians.

Sangamo Therapeutics' Fabry Disease Candidate ST-920 Gains Accelerated Approval Pathway

Sangamo Therapeutics' shares surged after the FDA agreed to a regulatory pathway for accelerated approval of isaralgagene civaparvovec (ST-920) for Fabry disease.
The FDA will consider data from the Phase I/II STAAR trial, using the rate of decline in eGFR at 52 weeks as the primary basis for approval.

FDA Approves Iterum Therapeutics' Orlynvah for Uncomplicated UTIs

The FDA has approved Iterum Therapeutics' Orlynvah for treating uncomplicated urinary tract infections (UTIs) in adult women with limited oral antibacterial options.
This marks the first approved indication for Orlynvah and the first FDA-approved product for Iterum Therapeutics, a clinical-stage pharmaceutical company.

Sarepta's Elevidys Receives Expanded FDA Approval for Duchenne Muscular Dystrophy

The FDA has granted expanded approval to Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy (DMD) patients, broadening the eligible patient population.
Elevidys, a gene therapy, now includes ambulatory and non-ambulatory DMD patients, marking a significant advancement in treatment options.

FDA Approves Geron's RYTELO™ (imetelstat) for Lower-Risk MDS

The FDA has approved Geron's RYTELO™ (imetelstat) for adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia and are unresponsive to or ineligible for erythropoiesis-stimulating agents (ESA).
The approval was based on the IMerge Phase 3 trial, where RYTELO™ significantly increased red blood cell transfusion independence compared to placebo, with nearly 40% achieving independence for at least eight weeks.

Reference News

[1]
Geron Stock Rallies More Than 60% in a Year: Here's Why
finance.yahoo.com · Jan 8, 2025

In 2024, Geron Corporation achieved FDA approval for Rytelo, targeting MDS with transfusion-dependent anemia, leading to...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy